Advertisement
Advertisement
PGEN
Precigen, Inc. Common Stock
3.90
USDSponsored
+0.80
+25.77%
Mar 26, 15:59 UTC -4
Closed
After-Market
3.92
+0.02
+0.41%
PGEN Earnings Reports
Positive Surprise Ratio
PGEN beat 12 of 41 last estimates.
29%
Next Report
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
$24.48M
/-$0.07
Implied change from Q4 25 (Revenue/ EPS)
+435.67%
/+600.00%
Implied change from Q1 25 (Revenue/ EPS)
+1725.50%
/--
Precigen, Inc. Common Stock earnings per share and revenue
On Mar 25, 2026, PGEN reported earnings of -0.01 USD per share (EPS) for Q4 25, beating the estimate of -0.08 USD, resulting in a 88.24% surprise. Revenue reached 4.57 million, compared to an expected 8.45 million, with a -45.93% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 24.48 million USD, implying an increase of 600.00% EPS, and increase of 435.67% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
FAQ
What were Precigen, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Precigen, Inc. Common Stock reported EPS of -$0.01, beating estimates by 88.24%, and revenue of $4.57M, -45.93% below expectations.
How did the market react to Precigen, Inc. Common Stock's Q4 2025 earnings?
The stock price moved -- 0%, changed from $3.51 before the earnings release to $3.51 the day after.
When is Precigen, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Precigen, Inc. Common Stock's next earnings report?
Based on 4
analysts, Precigen, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of $24.48M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement